Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00054211" target="_blank" >RIV/00216224:14110/11:00054211 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/11:#0001204
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II
Original language description
Purpose: To report results of retrospective, consecutive, noncomparative case series of moderate and severe stage 3 retinopathy of prematurity (ROP) in zone I or posterior zone II treated by bilateral intravitreal injections of pegaptanib or bevacizumaband diode laser photocoagulation. 32 infants weighing from 545 g to 1,150 g at birth (mean, 742.8 g) with gestational ages from 22 weeks to 28 weeks (mean, 24.1 weeks) received intravitreal injections of pegaptanib (0,15mg) or bevacizumab (0.625 mg ) at9.0 weeks to 14.0 weeks of age (mean, 10.5 weeks) and after 1 week had diode laser therapy. Length of follow-up was from 15.0 weeks to 95.0 weeks (mean, 56.5 weeks). Only patients with bilateral moderate or severe stage 3 ROP in Zone I or posterior ZoneII with or without plus-disease were considered candidates for this study. All cases were photographed by the RetCam Imaging System immediately before and 1week, 1,2, and 3months after the bilateral treatment.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FF - ENT (ie. ear, nose, throat), ophthalmology, dentistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9892" target="_blank" >NS9892: Intravitreal injection of selective inhibitor of vascular endothelial growth factor (anti -VEGF), pegaptanib sodium, in the treatment of retinopathy of prematurity</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů